WO1997024446A3 - Gene delivery vehicle-targeting ligands - Google Patents

Gene delivery vehicle-targeting ligands Download PDF

Info

Publication number
WO1997024446A3
WO1997024446A3 PCT/US1996/020295 US9620295W WO9724446A3 WO 1997024446 A3 WO1997024446 A3 WO 1997024446A3 US 9620295 W US9620295 W US 9620295W WO 9724446 A3 WO9724446 A3 WO 9724446A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene delivery
delivery vehicle
fusion proteins
targeting ligands
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/020295
Other languages
French (fr)
Other versions
WO1997024446A2 (en
Inventor
Sunil Chada
Theresa Banks
Margaret D Moore
Stephen M W Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Priority to EP96945228A priority Critical patent/EP0870040A2/en
Publication of WO1997024446A2 publication Critical patent/WO1997024446A2/en
Publication of WO1997024446A3 publication Critical patent/WO1997024446A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fusion proteins composed of an MHC Class I molecule, MHC Class II molecule, or β2 microglobulin, and a targeting ligand are disclosed. Also disclosed are nucleic acid molecules which encode such fusion proteins as well as suitable expression cassettes and host cells. Also provided are methods for targeting a gene delivery vehicle to a selected cell type utilizing gene delivery vehicles which contain on their surfaces one of the above-mentioned fusion proteins.
PCT/US1996/020295 1995-12-29 1996-12-20 Gene delivery vehicle-targeting ligands Ceased WO1997024446A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96945228A EP0870040A2 (en) 1995-12-29 1996-12-20 Gene delivery vehicle-targeting ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58054195A 1995-12-29 1995-12-29
US941195P 1995-12-29 1995-12-29
US60/009,411 1995-12-29
US08/580,541 1995-12-29

Publications (2)

Publication Number Publication Date
WO1997024446A2 WO1997024446A2 (en) 1997-07-10
WO1997024446A3 true WO1997024446A3 (en) 1997-10-23

Family

ID=26679433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/020295 Ceased WO1997024446A2 (en) 1995-12-29 1996-12-20 Gene delivery vehicle-targeting ligands

Country Status (2)

Country Link
EP (1) EP0870040A2 (en)
WO (1) WO1997024446A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
WO1999055893A1 (en) * 1998-04-29 1999-11-04 University Of Southern California Retroviral vectors including modified envelope escort proteins
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US6682741B1 (en) * 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
EP1168918A4 (en) * 1999-03-03 2002-08-21 Univ Pennsylvania VACCINE AND GENE THERAPY COMPOSITIONS, METHODS OF PRODUCING AND USES THEREOF
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2008243241B2 (en) * 2001-06-19 2011-11-17 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
KR101442209B1 (en) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. Fusion proteins, uses thereof and methods for their production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352761A2 (en) * 1988-07-28 1990-01-31 BEHRINGWERKE Aktiengesellschaft Antigens composed of "major histocompatibility complex" class I antigens and specific carrier molecules, their production and use
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO1995030014A1 (en) * 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
WO1995031566A1 (en) * 1994-05-13 1995-11-23 Chiron Viagene, Inc. Compositions and methods for targeting gene delivery vehicles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352761A2 (en) * 1988-07-28 1990-01-31 BEHRINGWERKE Aktiengesellschaft Antigens composed of "major histocompatibility complex" class I antigens and specific carrier molecules, their production and use
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO1995030014A1 (en) * 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
WO1995031566A1 (en) * 1994-05-13 1995-11-23 Chiron Viagene, Inc. Compositions and methods for targeting gene delivery vehicles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. HEKELE ET AL.: "Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.", INTERNATIONAL JOURNAL OF CANCER, vol. 68, no. 2, 9 October 1996 (1996-10-09), COPENHAGEN, DK, pages 232 - 238, XP000646379 *
C. FRASER ET AL.: "Specific unresponsiveness to a retrovirally-transferred class I antigen is controlled through the helper pathway.", THE JOURNAL OF IMMUNOLOGY, vol. 154, no. 4, 15 February 1995 (1995-02-15), BALTIMORE, MD, USA, pages 1587 - 1595, XP002039052 *
S. CHUNG ET AL.: "Functional three-domain single-chain T-cell receptors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, no. 26, 20 December 1994 (1994-12-20), WASHINGTON, DC, USA, pages 12564 - 12568, XP002039051 *

Also Published As

Publication number Publication date
WO1997024446A2 (en) 1997-07-10
EP0870040A2 (en) 1998-10-14

Similar Documents

Publication Publication Date Title
WO1997024446A3 (en) Gene delivery vehicle-targeting ligands
EP0830459A4 (en) Reverse two-hybrid systems
WO1997025416A3 (en) Novel dna glycosylases and their use
EP1754788A3 (en) Prostate-specific membrane antigen and uses thereof
WO1999006557A3 (en) Mammalian cell membrane proteins; related reagents
IL143238A0 (en) Dna-protein fusions and uses thereof
WO1997003192A3 (en) Chromosome 1 gene and gene products related to alzheimer's disease
EP1477561A3 (en) Molecule assigning genotype to phenotype and use thereof
EP0845032A3 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
CA2259421A1 (en) Labelling and selection of molecules
CA2212185A1 (en) Methods for the isothermal amplification of nucleic acid molecules
AU4818599A (en) Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods
AU2023199A (en) Methods, systems, and kits for intravascular nucleic acid delivery
WO2000054046A3 (en) Universal protein array system
AU3471697A (en) An improved method for the capillary electrophoresis of nucleic acids, proteins and low molecular charged compounds
CA2139667A1 (en) Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes
ATE319854T1 (en) ENZYMACTIVE DNA MOLECULES
ATE315087T1 (en) NOVEL P53-RESPONSIVE GENES
DE69632827D1 (en) MATERIALS AND METHODS IN CONNECTION WITH BINDING AND PRESENTATION OF SUBSTANCES ON CELL SURFACES
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2000069897A3 (en) Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
EP1980573A3 (en) Isolated dendritic cell membrane protein genes
AU1113999A (en) Target sequences for synthetic molecules and methods of using same
WO2000001827A3 (en) Polyketides, their preparation, and materials for use therein
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996945228

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996945228

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996945228

Country of ref document: EP